Compare Stocks: AVTE, RARE, KOD, and SLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$21.23 -5.9%	$20.82	$89.95 ▼ $99.05	$615.35M	0.95	53,591 shs	936,622 shs
KOD Kodiak Sciences	$38.33 -3.8%	$39.90	$8.29 ▼ $47.84	$2.50B	2.21	580,094 shs	509,119 shs
RARE Ultragenyx Pharmaceutical	$25.83 +2.0%	$28.58	$18.29 ▼ $39.89	$2.50B	0.35	2.11 million shs	2.39 million shs
SLS SELLAS Life Sciences Group	$15.46 +15.4%	$11.85	$1.39 ▼ $15.88	$2.71B	2.48	6.14 million shs	15.20 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-4.25%	-2.84%	+14.64%	-3.88%	+206.39%
KOD Kodiak Sciences	-0.57%	-0.35%	-6.08%	+9.96%	+319.37%
RARE Ultragenyx Pharmaceutical	-3.51%	-4.02%	-11.53%	+8.25%	-13.76%
SLS SELLAS Life Sciences Group	-3.25%	+8.41%	+3.88%	+72.24%	+624.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$21.23 -5.9%	$20.82	$89.95 ▼ $99.05	$615.35M	0.95	53,591 shs	936,622 shs
KOD Kodiak Sciences	$38.33 -3.8%	$39.90	$8.29 ▼ $47.84	$2.50B	2.21	580,094 shs	509,119 shs
RARE Ultragenyx Pharmaceutical	$25.83 +2.0%	$28.58	$18.29 ▼ $39.89	$2.50B	0.35	2.11 million shs	2.39 million shs
SLS SELLAS Life Sciences Group	$15.46 +15.4%	$11.85	$1.39 ▼ $15.88	$2.71B	2.48	6.14 million shs	15.20 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	-4.25%	-2.84%	+14.64%	-3.88%	+206.39%
KOD Kodiak Sciences	-0.57%	-0.35%	-6.08%	+9.96%	+319.37%
RARE Ultragenyx Pharmaceutical	-3.51%	-4.02%	-11.53%	+8.25%	-13.76%
SLS SELLAS Life Sciences Group	-3.25%	+8.41%	+3.88%	+72.24%	+624.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
KOD Kodiak Sciences	2.63	Moderate Buy	$48.14	25.60% Upside
RARE Ultragenyx Pharmaceutical	2.84	Moderate Buy	$58.89	127.99% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-35.32% Downside

Current Analyst Ratings Breakdown

Latest AVTE, RARE, KOD, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$67.00 ➝ $74.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$81.00 ➝ $83.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $58.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$45.00 ➝ $46.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$96.00 ➝ $103.00
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
8/12/2026	SLS SELLAS Life Sciences Group	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/5/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
8/4/2026	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $35.00
8/3/2026	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $66.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
RARE Ultragenyx Pharmaceutical	$673M	3.78	N/A	N/A	($2.95) per share	-8.76
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	N/A
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	N/A

Latest AVTE, RARE, KOD, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
KOD Kodiak Sciences	N/A	2.49	2.49
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
KOD Kodiak Sciences	89.06%
RARE Ultragenyx Pharmaceutical	97.67%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
KOD Kodiak Sciences	44.40%
RARE Ultragenyx Pharmaceutical	5.20%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
KOD Kodiak Sciences	90	62.85 million	34.94 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable
SLS SELLAS Life Sciences Group	10	201.95 million	199.32 million	Not Optionable

AVTE, RARE, KOD, and SLS Headlines

Recent News About These Companies

Traders Purchase Large Volume of SELLAS Life Sciences Group Call Options (NASDAQ:SLS)

August 21 at 3:19 PM | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10% Higher - Still a Buy?

August 21 at 2:59 PM | marketbeat.com

SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress

August 21 at 5:43 AM | finance.yahoo.com

Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial

August 17, 2026 | finance.yahoo.com

This One Data Readout Could Make Or Break Sellas Life Sciences Group

August 13, 2026 | seekingalpha.com

Sellas’ experimental drug SLS009 appears to be leading the CDK9 race, says Alliance Global – analyst sees about 200% upside potential

August 12, 2026 | msn.com

Investors Buy High Volume of SELLAS Life Sciences Group Put Options (NASDAQ:SLS)

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Time to Buy?

August 12, 2026 | marketbeat.com

SELLAS Life Sciences Group, Inc. $SLS is Dagco Inc.'s 10th Largest Position

August 12, 2026 | marketbeat.com

Sellas Life Sciences reports wider loss as REGAL trial nears final analysis

August 11, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

August 11, 2026 | marketbeat.com

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 6.8% - What's Next?

August 10, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires 221,957 Shares of SELLAS Life Sciences Group, Inc. $SLS

August 10, 2026 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 12.4% Higher - Time to Buy?

August 3, 2026 | marketbeat.com

SLS stock eyes green start to August after nearly $6M in fresh institutional buying: Retail stays bearish

August 3, 2026 | msn.com

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

August 2, 2026 | seekingalpha.com

SELLAS Life Sciences Group (SLS) Expected to Release Quarterly Earnings on Thursday

August 1, 2026 | marketbeat.com

SLS stock in spotlight after Vanguard Capital discloses 5.19% stake – retail calls it 'huge vote of conviction' as AML trial readout nears

July 31, 2026 | msn.com

SLS stock turns green after 3-day rout: Five investors add shares as key AML trial nears final trigger

July 31, 2026 | msn.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 12.5% - Should You Sell?

July 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AVTE, RARE, KOD, and SLS Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$21.23 -1.32 (-5.85%)

As of 08/20/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Kodiak Sciences NASDAQ:KOD

$38.33 -1.51 (-3.79%)

As of 04:00 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$25.83 +0.51 (+2.01%)

As of 04:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

SELLAS Life Sciences Group NASDAQ:SLS

$15.46 +2.06 (+15.37%)

As of 04:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, RARE, KOD, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, RARE, KOD, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, RARE, KOD, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, RARE, KOD, and SLS Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Kodiak Sciences NASDAQ:KOD

Ultragenyx Pharmaceutical NASDAQ:RARE

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AVTE, RARE, KOD, and SLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AVTE, RARE, KOD, and SLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AVTE, RARE, KOD, and SLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AVTE, RARE, KOD, and SLS Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

Kodiak Sciences NASDAQ:KOD

Ultragenyx Pharmaceutical NASDAQ:RARE

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools